 Nathan Dahl
Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 7 | 2023 | 306 | 3.280 |
Why?
| | Brain Stem Neoplasms | 3 | 2023 | 90 | 1.610 |
Why?
| | Brain Neoplasms | 3 | 2021 | 1022 | 0.970 |
Why?
| | Pyrimidinones | 1 | 2023 | 86 | 0.860 |
Why?
| | Adenomatous Polyposis Coli | 2 | 2019 | 31 | 0.830 |
Why?
| | Pyridones | 1 | 2023 | 119 | 0.830 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.800 |
Why?
| | Receptor, trkB | 1 | 2021 | 28 | 0.780 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 59 | 0.750 |
Why?
| | Genes, APC | 2 | 2019 | 13 | 0.750 |
Why?
| | beta Catenin | 2 | 2019 | 219 | 0.730 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 33 | 0.730 |
Why?
| | Oncologists | 1 | 2020 | 31 | 0.720 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 134 | 0.700 |
Why?
| | Bevacizumab | 1 | 2019 | 124 | 0.680 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 446 | 0.660 |
Why?
| | Craniopharyngioma | 1 | 2019 | 70 | 0.660 |
Why?
| | Radiotherapy | 1 | 2019 | 187 | 0.640 |
Why?
| | Radiation Injuries | 1 | 2019 | 131 | 0.640 |
Why?
| | Brain Diseases | 1 | 2019 | 140 | 0.630 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 165 | 0.630 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 128 | 0.620 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 219 | 0.620 |
Why?
| | Chordoma | 1 | 2017 | 13 | 0.610 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 29 | 0.600 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 38 | 0.590 |
Why?
| | Gardner Syndrome | 1 | 2016 | 2 | 0.580 |
Why?
| | Fibroma | 1 | 2016 | 20 | 0.560 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2015 | 21 | 0.550 |
Why?
| | Histones | 2 | 2020 | 552 | 0.540 |
Why?
| | Chromosome Deletion | 1 | 2015 | 95 | 0.530 |
Why?
| | Niacinamide | 1 | 2015 | 70 | 0.530 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 83 | 0.520 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 85 | 0.520 |
Why?
| | Azacitidine | 1 | 2015 | 119 | 0.500 |
Why?
| | Mutation | 3 | 2021 | 3457 | 0.460 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 532 | 0.340 |
Why?
| | Antineoplastic Agents | 2 | 2022 | 1974 | 0.340 |
Why?
| | Child, Preschool | 5 | 2021 | 9491 | 0.260 |
Why?
| | Child | 6 | 2023 | 19129 | 0.260 |
Why?
| | Humans | 14 | 2023 | 118974 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 35 | 0.230 |
Why?
| | Epigenomics | 2 | 2020 | 107 | 0.220 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 57 | 0.220 |
Why?
| | Brain Stem | 1 | 2023 | 104 | 0.210 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2023 | 202 | 0.190 |
Why?
| | Fatal Outcome | 1 | 2021 | 287 | 0.180 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 51 | 0.180 |
Why?
| | Narration | 1 | 2020 | 48 | 0.180 |
Why?
| | Attitude to Death | 1 | 2020 | 61 | 0.180 |
Why?
| | Chromatin | 2 | 2020 | 441 | 0.180 |
Why?
| | DNA Repair | 1 | 2021 | 198 | 0.170 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 135 | 0.170 |
Why?
| | Cell Line, Tumor | 3 | 2022 | 2851 | 0.170 |
Why?
| | Medulloblastoma | 1 | 2021 | 177 | 0.170 |
Why?
| | Female | 7 | 2021 | 61565 | 0.170 |
Why?
| | Necrosis | 1 | 2019 | 230 | 0.160 |
Why?
| | Point Mutation | 1 | 2019 | 228 | 0.160 |
Why?
| | Rhabdomyoma | 1 | 2017 | 10 | 0.150 |
Why?
| | Angiomyolipoma | 1 | 2017 | 18 | 0.150 |
Why?
| | Dexamethasone | 1 | 2019 | 320 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3174 | 0.150 |
Why?
| | Heart Neoplasms | 1 | 2017 | 50 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2019 | 749 | 0.140 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2015 | 15 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 539 | 0.140 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 544 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 289 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2019 | 545 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1390 | 0.130 |
Why?
| | Pilot Projects | 1 | 2019 | 1419 | 0.130 |
Why?
| | Stem Cell Transplantation | 1 | 2015 | 153 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1167 | 0.120 |
Why?
| | Male | 5 | 2021 | 57801 | 0.120 |
Why?
| | Infant | 2 | 2017 | 8293 | 0.110 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 755 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 334 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 965 | 0.110 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2445 | 0.100 |
Why?
| | Phenotype | 1 | 2019 | 3003 | 0.100 |
Why?
| | Aging | 1 | 2020 | 1670 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2017 | 762 | 0.090 |
Why?
| | Brain | 1 | 2020 | 2490 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 900 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2220 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2021 | 2275 | 0.060 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 74 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 226 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 165 | 0.050 |
Why?
| | Adolescent | 1 | 2019 | 18480 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2021 | 115 | 0.050 |
Why?
| | Astrocytoma | 1 | 2020 | 113 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 576 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 12978 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 445 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 248 | 0.040 |
Why?
| | Mice | 2 | 2022 | 15520 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1753 | 0.030 |
Why?
| | Apoptosis | 1 | 2022 | 2484 | 0.030 |
Why?
| | Animals | 2 | 2022 | 33381 | 0.020 |
Why?
|
|
Dahl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|